QC
SNDX icon

Quadrature Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Quadrature Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,129
Closed -$283K – 2020
2026
Q1 		$283K Sell
12,129
-2,757
-19% -$59.9K ﹤0.01% 1004
2025
Q4 		$313K Sell
14,886
-17,474
-54% -$305K ﹤0.01% 833
2025
Q3 		$498K Buy
+32,360
New +$424K 0.01% 523

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Quadrature Capital's SNDX Position: Q2 2026 in Review

Quadrature Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 12,129 shares — an estimated $283K sold.

Quadrature Capital first reported a position in SNDX in Q3 2025 and held it in 3 quarters. The position peaked at $498K in Q3 2025. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Quadrature Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 12,129 Syndax Pharmaceuticals shares in Q2 2026, an estimated $283K.
  • Quadrature Capital first reported a position in Syndax Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Quadrature Capital's Syndax Pharmaceuticals position peaked at $498K in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.